Palvella Therapeutics (PVLA) Current Assets (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Current Assets data on file, last reported at $263.2 million in Q1 2026.

• On a quarterly basis, Current Assets rose 231.36% year-over-year to $263.2 million in Q1 2026; TTM through Mar 2026 was $263.2 million, a 231.36% increase from a year earlier, with the FY2025 full-year figure at $59.0 million, down 33.15% from the prior year.
• Current Assets for Q1 2026 stood at $263.2 million, up from $59.0 million in the prior quarter.
• Over the last five years, Current Assets for PVLA reached as high as $263.2 million in Q1 2026 and fell as low as $7.5 million in Q4 2023.
• Historically, Current Assets has averaged $84.2 million across 5 years, with a median of $73.6 million in 2022.
• Across the five-year window, Current Assets sank 89.72% in 2023 and soared 1068.97% in 2024, its largest moves.
• Year by year, Current Assets stood at $73.4 million in 2022, then sank by 89.72% to $7.5 million in 2023, then surged by 1068.97% to $88.2 million in 2024, then sank by 33.15% to $59.0 million in 2025, then soared by 346.25% to $263.2 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $263.2 million in Q1 2026, $59.0 million in Q4 2025, and $66.9 million in Q3 2025.